Int Conf AIDS 2004 Jul 11-16; 15:(abstract no. A10160)
Babkina IN, Pozdnyakov SG, Ryazankin IA, Babkin IV, Shchelkunov SN SRC VB Vector, Koltsovo, Russian Federation
The absence of effective anti-HIV vaccines and a rapid growth of HIV cases in both Russia and the world require new approaches to development of new generation efficient vaccines against HIV infection. The goal of this project is to design anti-HIV DNA vaccines and vaccines involving recombinant vaccinia viruses. Such vaccines would lack many shortcomings of the vaccines involving natural antigens. In particular, an artificial immunogen may meet a number of safety requirements: may not enhance infection, may not develop immunopathology, may not inhibit protective immunity, may not form autoimmune response, and may not be a potential oncogene. Therefore, artificial immunogens have a potential of boosting the immune response to HIV compared with the naturally going HIV infection. To reach this goal, genetic engineering techniques were used to construct several variants of expression plasmids with artificial gene TBI or gene gp120, using the plasmids pBKRSV, pcDNA3.1-mycchislacZ(-) and pDOLHIVenv. We plan to design recombinant live polyvalent vaccines using attenuated vaccinia virus vector (L-IVP strain Lister). A vector tested earlier pVar15 was used as an integrating plasmid. Seven variant of such plasmid will be obtained as well as seven variants of recombinant virus with the following genes: ENV2 (gp120dV3 with deleted V3 loop), STBI, STBI-anchor, IL-2, TBI-HBsAg, TCI, and TCI-HBsAg.
Keywords: AEGIS, HIV, Acquired Immunodeficiency Syndrome, HIV Seropositivity, AIDS Vaccines, HIV Infections, HIV Antibodies, HIV Envelope Protein gp120, Vaccinia virus, HIV Envelope Protein gp160, HIV Antigens, Russia, immunology
